Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 48 clinical trials
RANKL Inhibition and Mammographic Breast Density (TRIDENT)

adoption of RANKL inhibition in primary breast cancer prevention are not yet available. The hypothesis is that RANKL inhibition with denosumab will decrease mammographic density in high-risk premenopausal

  • 0 views
  • 23 Apr, 2022
  • 1 location
Novel Combination Therapy for Osteoporosis in Men (Osteo-Men)

Osteoporotic fractures are a key health problem in older men. Although there are drugs approved to treat osteoporosis in men [bisphosphonates, denosumab, and teriparatide (TPTD) or PTH(1-34

  • 34 views
  • 26 Feb, 2022
  • 1 location
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

The aim of the trial is to test the hypothesis that the benefit of denosumab is maintained if administered only every 12 weeks as compared to every 4 weeks.

bisphosphonate
bone scan
ct scan
pet/ct scan
denosumab
  • 72 views
  • 21 Apr, 2022
  • 62 locations
A Study to Evaluate the Efficacy Pharmacodynamics Safety and Immunogenicity of FKS518 in Postmenopausal Women With Osteoporosis

to demonstrate equivalent efficacy and pharmacodynamics of the proposed biosimilar denosumab FKS518 to US-Prolia in women with PMO.

x-rays
prolia
x-ray absorptiometry
hysterectomy
bone mineral density
  • 0 views
  • 27 Oct, 2021
  • 11 locations
Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

This randomized open label clinical trial will evaluate the effect of continued denosumab alone over 18 months versus denosumab with added abaloparatide for 18 months. 70 postmenopausal women

  • 0 views
  • 23 Feb, 2021
  • 1 location
Denosumab Sequential Therapy

Denosumab is a potent anti-resorptive agent and is now widely used in the treatment of osteoporosis. Although denosumab has excellent effect to increase bone mass and prevent fracture in FREEDOM

  • 0 views
  • 27 Jan, 2021
  • 1 location
Denosumab for Smoldering Multiple Myeloma

This study will assess the safety and tolerability of denosumab in smoldering multiple myeloma subjects as well to see if denosumab can reduce subjects' risk of getting multiple myeloma.

bone marrow plasma cells
anemia
hypercalcemia
hysterectomy
vitamin d
  • 0 views
  • 04 Feb, 2022
  • 1 location
Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma (KEYPAD)

This Single-arm, multicentre, phase 2 trial aims determine the activity and safety of pembrolizumab and denosumab in advanced clear cell renal cell carcinoma (ccRCC).

clear cell renal cell carcinoma
carcinoma
liver metastasis
renal function
serum calcium
  • 504 views
  • 22 Mar, 2022
  • 15 locations
The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury

The purpose of this study is to determine the usefulness of a drug, denosumab, to prevent the loss of bone in participants legs due to SCI. This drug is FDA approved to treat osteoporosis in

spinal injury
spinal cord disorder
spinal cord
cancer
  • 137 views
  • 27 Feb, 2022
  • 1 location
Bisphosphonates for Prevention of Post-Denosumab Bone Loss

The primary goal of the study is to assess the extent to which bisphosphonate therapy will prevent decreases in bone mass that may occur after cessation of denosumab in premenopausal women with

bisphosphonate therapy
bisphosphonate
forteo
teriparatide
zoledronic acid
  • 78 views
  • 03 Mar, 2022